Table 1.

Clinical and pathological data of the patients included in this study

(A) IPO Porto’s cohort
Clinicopathological features	MNPT	PCa
Patients, n	14	100
Median age, years (range)	65 (49–80)	65 (49–75)
PSA (ng/mL), median (range)	n.a.	8.45 (3.5–23)
pT2	n.a.	60 (60%)
pT3	n.a.	40 (40%)
< 7	n.a.	36 (36%)
= 7	n.a.	58 (58%)
> 7	n.a.	6 (6%)
(B) TCGA’s cohort
Clinicopathological Features	NAT	PCa
Patients, n	52	497
Median age, years (range)	61 (43–72)	61 (41–78)
pT2	29 (56%)	189 (38%)
pT3	21 (40%)	292 (59%)
pT4	2 (4%)	10 (2%)
< 7	5 (10%)	45 (9%)
= 7	40 (77%)	248 (50%)
> 7	7 (13%)	204 (41%)

MNPT morphologically normal prostate tissue, PCa prostate cancer, NAT normal adjacent tissue, n.a. not applicable

(A) IPO Porto’s cohort (B) TCGA’s cohort